<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197573</url>
  </required_header>
  <id_info>
    <org_study_id>CCIRB: 10-365</org_study_id>
    <secondary_id>R38OT15491</secondary_id>
    <nct_id>NCT01197573</nct_id>
  </id_info>
  <brief_title>Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy</brief_title>
  <official_title>Enhancing DCD Utilization With Thrombolytic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Resources and Services Administration (HRSA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that delayed graft function and ITBS events may be related to small blood
      clots (microthrombi) that collect in the kidneys and liver after cardiac death. Treatment of
      the DCD organs with a thrombolytic agent prior to implantation may reduce post-transplant
      morbidity and mortality, and may ultimately result in a greater number of transplantable
      livers and kidneys.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The waiting list for kidney and liver transplantation continues to increase in the United
      States, and therefore the need grows for additional donor organs. Utilization of organs
      donated after cardiac death (DCD) could be one way to increase organ availability, however
      there are risks associated with poorer clinical outcomes, including delayed graft function
      and in livers specifically, ischemic-type biliary strictures (ITBS). We hypothesize that
      delayed graft function and ITBS events may be related to small blood clots (microthrombi)
      that collect in the kidneys and liver after cardiac death. Treatment of the DCD organs with a
      thrombolytic agent prior to implantation may reduce post-transplant morbidity and mortality,
      and may ultimately result in a greater number of transplantable livers and kidneys.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delayed Kidney Graft Function</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Primary Liver Graft Nonfunction</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Liver Ischemic-Type Biliary Strictures</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Standard DCD liver transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard method of liver transplant utilizing a DCD organ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rTPA Treatment Liver Transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ex-vivo treatment of liver donated after cardiac death (DCD) with rTPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard DCD kidney transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard method of kidney transplant utilizing a DCD organ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rTPA Treatment Kidney Transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ex-vivo treatment of kidney donated after cardiac death (DCD) with rTPA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rTPA Treatment</intervention_name>
    <description>Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation</description>
    <arm_group_label>rTPA Treatment Kidney Transplant</arm_group_label>
    <arm_group_label>rTPA Treatment Liver Transplant</arm_group_label>
    <other_name>Alteplase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No TPA Treatment</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Standard DCD kidney transplant</arm_group_label>
    <arm_group_label>Standard DCD liver transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 18 years and older

          -  Subjects willing/able to provide written consent

          -  Subjects willing/able to comply with study requirements

          -  Subjects who will receive a solitary organ transplant

        Exclusion Criteria:

          -  Subjects requiring multi-organ transplants

          -  Women who are pregnant

          -  Subjects with current severe systemic infection

          -  Subjects with an active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bijan Eghtesad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals / Case medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <results_first_submitted>June 12, 2018</results_first_submitted>
  <results_first_submitted_qc>July 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2018</results_first_posted>
  <last_update_submitted>July 31, 2018</last_update_submitted>
  <last_update_submitted_qc>July 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Bijan Eghtesad, MD</investigator_full_name>
    <investigator_title>HPBT Staff Surgeon</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>DCD donors from 2010 to 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard DCD Liver Transplant</title>
          <description>Standard method of liver transplant utilizing a DCD organ</description>
        </group>
        <group group_id="P2">
          <title>rTPA Treatment - Liver</title>
          <description>Ex-vivo treatment of liver donated after cardiac death (DCD)with rTPA
rTPA Treatment: Ex-vivo treatment of DCD liver with rTPA (recombinant tissue plasminogen activator)prior to implantation</description>
        </group>
        <group group_id="P3">
          <title>Standard DCD Kidney Transplant</title>
          <description>Standard method of kidney transplant utilizing a DCD organ</description>
        </group>
        <group group_id="P4">
          <title>rTPA Treatment - Kidney</title>
          <description>Ex-vivo treatment of kidney donated after cardiac death (DCD)with rTPA
rTPA Treatment: Ex-vivo treatment of DCD kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard DCD Liver Transplant</title>
          <description>Standard method of liver transplant utilizing a DCD organ</description>
        </group>
        <group group_id="B2">
          <title>rTPA Treatment - Liver</title>
          <description>Ex-vivo treatment of liver donated after cardiac death (DCD)with rTPA
rTPA Treatment: Ex-vivo treatment of DCD liver with rTPA (recombinant tissue plasminogen activator)prior to implantation</description>
        </group>
        <group group_id="B3">
          <title>rTPA Treatment - Kidney</title>
          <description>Ex-vivo treatment of kidney donated after cardiac death (DCD)with rTPA
rTPA Treatment: Ex-vivo treatment of DCD kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation</description>
        </group>
        <group group_id="B4">
          <title>Standard DCD Kidney Transplant</title>
          <description>Standard method of kidney transplant utilizing a DCD organ</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Delayed Kidney Graft Function</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rTPA Treatment - Kidney</title>
            <description>Ex-vivo treatment of kidney donated after cardiac death (DCD)with rTPA
rTPA Treatment: Ex-vivo treatment of DCD kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation</description>
          </group>
          <group group_id="O2">
            <title>Standard DCD Kidney Transplant</title>
            <description>Standard method of kidney transplant utilizing a DCD organ</description>
          </group>
        </group_list>
        <measure>
          <title>Delayed Kidney Graft Function</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Primary Liver Graft Nonfunction</title>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard DCD Liver Transplant</title>
            <description>Standard method of liver transplant utilizing a DCD organ</description>
          </group>
          <group group_id="O2">
            <title>rTPA Treatment</title>
            <description>Ex-vivo treatment of liver donated after cardiac death (DCD)with rTPA
rTPA Treatment: Ex-vivo treatment of DCD liver with rTPA (recombinant tissue plasminogen activator)prior to implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Primary Liver Graft Nonfunction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Liver Ischemic-Type Biliary Strictures</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard DCD Liver Transplant</title>
            <description>Standard method of liver transplant utilizing a DCD organ</description>
          </group>
          <group group_id="O2">
            <title>rTPA Treatment</title>
            <description>Ex-vivo treatment of liver donated after cardiac death (DCD)with rTPA
rTPA Treatment: Ex-vivo treatment of DCD liver with rTPA (recombinant tissue plasminogen activator)prior to implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Liver Ischemic-Type Biliary Strictures</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One Year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard DCD Liver Transplant</title>
          <description>Standard method of liver transplant utilizing a DCD organ</description>
        </group>
        <group group_id="E2">
          <title>rTPA Treatment - Liver</title>
          <description>Ex-vivo treatment of liver donated after cardiac death (DCD)with rTPA
rTPA Treatment: Ex-vivo treatment of DCD liver with rTPA (recombinant tissue plasminogen activator)prior to implantation</description>
        </group>
        <group group_id="E3">
          <title>rTPA Treatment - Kidney</title>
          <description>Ex-vivo treatment of kidney donated after cardiac death (DCD)with rTPA
rTPA Treatment: Ex-vivo treatment of DCD kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation</description>
        </group>
        <group group_id="E4">
          <title>Standard DCD Kidneytransplant</title>
          <description>Standard method of kidney transplant utilizing a DCD organ</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Primary non -function</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <description>Necrotic Right Colon</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary Leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Delayed Graft Function</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="33"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bijan Eghtesad, MD</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216 444-9898</phone>
      <email>eghtesb@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

